Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.67 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659474 | 0.88 | ADORA3 (0.65) | ADORA3ADORA1DNPH1 | |
| SCHEMBL6659300 | 0.82 | ADORA1 (0.72) | ADORA3ADORA1DNPH1 | |
| SCHEMBL6659305 | 0.82 | ADORA1 (0.72) | ADORA3ADORA1DNPH1 | |
| SCHEMBL6559701 | 0.81 | ADORA3 (0.77) | ADORA3ADORA1DNPH1 | |
| SCHEMBL6559694 | 0.81 | ADORA3 (0.77) | ADORA3ADORA1DNPH1 | |
| SCHEMBL6657697 | 0.80 | ADORA3 (0.81) | ADORA3ADORA1DNPH1 | |
| Gr-190178 SCHEMBL6559897 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1DNPH1 | |
| SCHEMBL6657691 | 0.80 | ADORA3 (0.81) | ADORA3ADORA1DNPH1 | |
| Gr-190178 SCHEMBL6559907 | 0.80 | ADORA3 (1.00) | ADORA3ADORA1DNPH1 | |
| SCHEMBL6661610 | 0.80 | ADORA1 (0.68) | ADORA3ADORA1DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | claimed |
| US-6544960-B1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-08 | — | — | US | claimed |
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6740644-B2 | ADENOSINE DERIVATIVES, AGONISTS AT THE ADENOSINE A1 RECEPTOR | SMITHKLINE BEECHAM CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20030158146-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | US | disclosed |
| US-6544960-B1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-08 | — | — | US | disclosed |
| EP-1030856-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024451-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158146-A1 | Chemical compounds | CNR1, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885DNPH1 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.